ASCO Oral: Phase III COSMIC-311 promises a new standard of care for patients with previously treated differentiated thyroid cancer
Selected as an Oral Presentation during the [...]
ASCO Oral: Landmark study rings in the first immune-based therapy for patients with resected, high-risk early-stage non-small cell lung cancer
Selected by the American Society of [...]
ASCO Plenary: PARPi prevents disease recurrence in BRCA-mutated high-risk, early stage breast cancer
Full results from the OlympiA Phase III, [...]
The COVID-19 pandemic: widening the gender gap in cancer research
Barcelona, May 25, 2021- Results from a survey [...]
Cemiplimab steps up as the first immune-based therapy to improve overall survival in patients with recurrent and/or metastatic cervical cancer
Barcelona, May 12, 2021- Cervical cancer is the [...]
Launched: VHIO’s Scientific Report 2020. A year of challenges, opportunities and hope
2020 was a year of darkness as [...]
VHIO is participating prominently in a study that seeks to evaluate the efficacy of a novel combination therapy in advanced pancreatic cancer
Ability Pharmaceuticals Announces the Inclusion of the [...]
Special VHIO-CaixaResearch Scientific Seminar: VHIO Meet the Editors with Miguel Foronda, Associate Editor, Nature Cancer
Launched back in 2019, our VHIO – CaixaResearch [...]
Novel anti-PD-1 therapy, dostarlimab, approved as a new therapeutic avenue for recurrent or advanced endometrial cancer in Europe
Supported by the preliminary results* reported from [...]
